Ian H De Boer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7933582/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2013, 24, 302-308.	3.0	862
2	Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 2532.	3.8	785
3	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 2014, 37, 2864-2883.	4.3	781
4	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2020, 98, S1-S115.	2.6	692
5	Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. JAMA - Journal of the American Medical Association, 2016, 316, 602.	3.8	669
6	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine, 2011, 365, 2366-2376.	13.9	507
7	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 1273-1284.	4.3	462
8	Diabetic Kidney Disease: A Report From an ADA ConsensusÂConference. American Journal of Kidney Diseases, 2014, 64, 510-533.	2.1	439
9	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nature Communications, 2016, 7, 10023.	5.8	412
10	Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care, 2015, 38, 1777-1803.	4.3	346
11	Calcium Plus Vitamin D Supplementation and the Risk of Incident Diabetes in the Women's Health Initiative. Diabetes Care, 2008, 31, 701-707.	4.3	333
12	Association between Physical Performance and All-Cause Mortality in CKD. Journal of the American Society of Nephrology: JASN, 2013, 24, 822-830.	3.0	332
13	Long-term Renal Outcomes of Patients with Type 1 Diabetes Mellitus and Microalbuminuria <subtitle>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</subtitle> <alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title> .	4.3	298
14	Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nature Communications, 2018, 9, 260.	5.8	295
15	Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living Individuals. Journal of the American College of Cardiology, 2012, 60, 200-207.	1.2	291
16	Type 1 Diabetes Mellitus and Cardiovascular Disease. Circulation, 2014, 130, 1110-1130.	1.6	277
17	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2010, 33, 1536-1543.	4.3	257
18	25-Hydroxyvitamin D Levels and Albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases, 2007, 50, 69-77.	2.1	255

#	Article	IF	CITATIONS
19	A Prospective Study of Frailty in Nephrology-Referred Patients With CKD. American Journal of Kidney Diseases, 2012, 60, 912-921.	2.1	246
20	25-Hydroxyvitamin D Levels Inversely Associate with Risk for Developing Coronary Artery Calcification. Journal of the American Society of Nephrology: JASN, 2009, 20, 1805-1812.	3.0	244
21	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	13.9	228
22	Vitamin D, Parathyroid Hormone, and Cardiovascular Events Among Older Adults. Journal of the American College of Cardiology, 2011, 58, 1433-1441.	1.2	224
23	Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2014, 37, 24-30.	4.3	197
24	Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen. Journal of the American Society of Nephrology: JASN, 2019, 30, 2000-2016.	3.0	135
25	The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney International, 2012, 82, 693-700.	2.6	133
26	Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. Diabetes, 2016, 65, 803-817.	0.3	131
27	Central Obesity, Incident Microalbuminuria, and Change in Creatinine Clearance in the Epidemiology of Diabetes Interventions and Complications Study. Journal of the American Society of Nephrology: JASN, 2007, 18, 235-243.	3.0	130
28	Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population. Circulation: Heart Failure, 2014, 7, 409-417.	1.6	130
29	Serum Phosphorus Concentrations in the Third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases, 2009, 53, 399-407.	2.1	129
30	Growth Differentiation Factor–15 and Risk of CKD Progression. Journal of the American Society of Nephrology: JASN, 2017, 28, 2233-2240.	3.0	127
31	The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension. Annals of Internal Medicine, 2017, 167, 630.	2.0	127
32	Common Genetic Variants Associate with Serum Phosphorus Concentration. Journal of the American Society of Nephrology: JASN, 2010, 21, 1223-1232.	3.0	123
33	Fibroblast Growth Factor-23 and Incident Atrial Fibrillation. Circulation, 2014, 130, 298-307.	1.6	123
34	Association of Serum Phosphate Levels With Aortic Valve Sclerosis and Annular Calcification. Journal of the American College of Cardiology, 2011, 58, 291-297.	1.2	120
35	Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease. JAMA Cardiology, 2017, 2, 314.	3.0	115
36	Longitudinal FGF23 Trajectories and Mortality in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 579-590.	3.0	114

#	Article	IF	CITATIONS
37	Genome-wide association study of kidney function decline in individuals of European descent. Kidney International, 2015, 87, 1017-1029.	2.6	113
38	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	2.0	110
39	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e265-e286.	1.6	107
40	Metabolomics and Gene Expression Analysis Reveal Down-regulation of the Citric Acid (TCA) Cycle in Non-diabetic CKD Patients. EBioMedicine, 2017, 26, 68-77.	2.7	103
41	Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus. Archives of Internal Medicine, 2008, 168, 1867.	4.3	98
42	Serum 25-Hydroxyvitamin D and Change in Estimated Glomerular Filtration Rate. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2141-2149.	2.2	97
43	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	2.6	94
44	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1969-1977.	2.2	93
45	Obesity and Change in Estimated GFR Among Older Adults. American Journal of Kidney Diseases, 2009, 54, 1043-1051.	2.1	90
46	Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Research and Care, 2020, 8, e000991.	1.2	87
47	Low Serum Bicarbonate and Kidney Function Decline: The Multi-Ethnic Study of Atherosclerosis (MESA). American Journal of Kidney Diseases, 2014, 64, 534-541.	2.1	82
48	GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2018, 72, 519-528.	2.1	82
49	Impaired Vitamin D Metabolism in CKD. Seminars in Nephrology, 2013, 33, 158-168.	0.6	78
50	Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1899.	3.8	77
51	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350.	3.0	76
52	Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy. Clinical Chemistry, 2017, 63, 1515-1526.	1.5	76
53	Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care, 2019, 42, 883-890.	4.3	76
54	Association of 25-Hydroxyvitamin D andÂParathyroid Hormone With Incident Hypertension. Journal of the American College of Cardiology, 2014, 63, 1214-1222.	1.2	73

Ian H De Boer

#	Article	IF	CITATIONS
55	Development and Validation of a Model to Predict 5-Year Risk of Death without ESRD among Older Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 363-371.	2.2	68
56	A reference tissue atlas for the human kidney. Science Advances, 2022, 8, .	4.7	67
57	Characterizing Antibody Cross-reactivity for Immunoaffinity Purification of Analytes prior to Multiplexed Liquid Chromatography–Tandem Mass Spectrometry. Clinical Chemistry, 2012, 58, 1711-1716.	1.5	66
58	Risk Factors for Rapid Kidney Function Decline Among African Americans: The Jackson Heart Study (JHS). American Journal of Kidney Diseases, 2016, 68, 229-239.	2.1	66
59	Estimated GFR and Circulating 24,25-Dihydroxyvitamin D3ÂConcentration: A Participant-Level Analysis of 5 Cohort Studies and Clinical Trials. American Journal of Kidney Diseases, 2014, 64, 187-197.	2.1	62
60	Association of Muscle Endurance, Fatigability, and Strength With Functional Limitation and Mortality in the Health Aging and Body Composition Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 284-291.	1.7	60
61	The 24,25 to 25-hydroxyvitamin D ratio and fracture risk in older adults: The cardiovascular health study. Bone, 2018, 107, 124-130.	1.4	60
62	Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2019, 73, 806-814.	2.1	58
63	25-Hydroxyvitamin D Concentration and Sleep Duration and Continuity: Multi-Ethnic Study of Atherosclerosis. Sleep, 2015, 38, 1305-1311.	0.6	57
64	Gender and Elevated Albumin Excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort: Role of Central Obesity. American Journal of Kidney Diseases, 2006, 47, 223-232.	2.1	56
65	Circulating Vitamin D Metabolites and Kidney Disease in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4780-4788.	1.8	55
66	Serum vitamin D and sex hormones levels in men and women: The Multi-Ethnic Study of Atherosclerosis (MESA). Maturitas, 2017, 96, 95-102.	1.0	54
67	Lipoprotein Abnormalities Associated with Mild Impairment of Kidney Function in the Multi-Ethnic Study of Atherosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 125-132.	2.2	53
68	Genetic Variants Associated with Circulating Parathyroid Hormone. Journal of the American Society of Nephrology: JASN, 2017, 28, 1553-1565.	3.0	52
69	Creatinine Clearance, Walking Speed, and Muscle Atrophy: AÂCohort Study. American Journal of Kidney Diseases, 2015, 65, 737-747.	2.1	51
70	Individualizing Blood Pressure Targets for People With Diabetes and Hypertension. JAMA - Journal of the American Medical Association, 2018, 319, 1319.	3.8	48
71	Comparison of Urinary Albumin-Creatinine Ratio and Albumin Excretion Rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1235-1242.	2.2	46
72	Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney International, 2015, 87, 1250-1257.	2.6	46

#	Article	IF	CITATIONS
73	A Cluster of Proteins Implicated in Kidney Disease Is Increased in High-Density Lipoprotein Isolated from Hemodialysis Subjects. Journal of Proteome Research, 2015, 14, 2792-2806.	1.8	46
74	NT-ProBNP and Troponin T and Risk of Rapid Kidney Function Decline and Incident CKD in Elderly Adults. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 205-214.	2.2	46
75	Prevalence of Hypertension and Cardiovascular Risk According to Blood Pressure Thresholds Used for Diagnosis. Hypertension, 2018, 72, 602-609.	1.3	46
76	Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 75, 235-244.	2.1	46
77	Metabolomic Markers of Kidney Function Decline in Patients With Diabetes: Evidence From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2020, 76, 511-520.	2.1	45
78	Modelling kidney disease using ontology: insights from the Kidney Precision Medicine Project. Nature Reviews Nephrology, 2020, 16, 686-696.	4.1	45
79	Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney International, 2013, 83, 323-330.	2.6	44
80	Vitamin D and glucose metabolism in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2008, 17, 566-572.	1.0	43
81	Polymorphic Human Sulfotransferase 2A1 Mediates the Formation of 25-Hydroxyvitamin D ₃ -3- <i>O</i> -Sulfate, a Major Circulating Vitamin D Metabolite in Humans. Drug Metabolism and Disposition, 2018, 46, 367-379.	1.7	41
82	Soluble ST2 and Galectin-3 and Progression of CKD. Kidney International Reports, 2019, 4, 103-111.	0.4	41
83	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818.	3.0	40
84	Pragmatic Clinical Trials in CKD: Opportunities and Challenges. Journal of the American Society of Nephrology: JASN, 2016, 27, 2948-2954.	3.0	39
85	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39
86	Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1498-1506.	2.2	38
87	Race, Ancestry, and Vitamin D Metabolism: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4337-e4350.	1.8	38
88	Kidney function is associated with an altered protein composition of high-density lipoprotein. Kidney International, 2017, 92, 1526-1535.	2.6	37
89	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861.	2.2	37
90	Serum Calcification Propensity and Clinical Events in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1562-1571.	2.2	36

#	Article	IF	CITATIONS
91	Associations of Circulating Lymphocyte Subpopulations with Type 2 Diabetes: Cross-Sectional Results from the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS ONE, 2015, 10, e0139962.	1.1	36
92	Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. Journal of the American Society of Nephrology: JASN, 2018, 29, 2583-2592.	3.0	35
93	Vitamin D metabolites and bone mineral density: The multi-ethnic study of atherosclerosis. Bone, 2015, 78, 186-193.	1.4	34
94	Mild elevations of urine albumin excretion are associated with atherogenic lipoprotein abnormalities in the Multi-Ethnic Study of Atheroslcerosis (MESA). Atherosclerosis, 2008, 197, 407-414.	0.4	33
95	Transethnic Evaluation Identifies Low-Frequency Loci Associated With 25-Hydroxyvitamin D Concentrations. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1380-1392.	1.8	33
96	Mortality Associated with Metformin Versus Sulfonylurea Initiation: A Cohort Study of Veterans with Diabetes and Chronic Kidney Disease. Journal of General Internal Medicine, 2018, 33, 155-165.	1.3	33
97	Diabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1384-1391.	2.2	32
98	Associations of Vitamin D–Binding Globulin and Bioavailable Vitamin D Concentrations With Coronary Heart Disease Events: The Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3075-3084.	1.8	30
99	Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis. Nephrology Dialysis Transplantation, 2014, 29, 2099-2105.	0.4	29
100	Self-Rated Health and Adverse Events in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2044-2051.	2.2	28
101	Dietary Acid Load is Associated With Serum Bicarbonate but not Insulin Sensitivity in Chronic Kidney Disease. , 2016, 26, 93-102.		27
102	Insulin resistance in chronic kidney disease: a step closer to effective evaluation and treatment. Kidney International, 2014, 86, 243-245.	2.6	26
103	Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults. Journal of the American Society of Nephrology: JASN, 2017, 28, 1239-1246.	3.0	26
104	Biomarkers of mineral metabolism and progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2019, 285, 79-86.	0.4	26
105	Fibroblast Growth Factorâ€23 and Frailty in Elderly Communityâ€Dwelling Individuals: The Cardiovascular Health Study. Journal of the American Geriatrics Society, 2016, 64, 270-276.	1.3	24
106	Genetic and Environmental Factors Are Associated with Serum 25-Hydroxyvitamin D Concentrations in Older African Americans. Journal of Nutrition, 2015, 145, 799-805.	1.3	23
107	Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. Journal of Diabetes and Its Complications, 2016, 30, 1467-1472.	1.2	23
108	Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease. Heart, 2018, 104, 1455-1460.	1.2	23

#	Article	IF	CITATIONS
109	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	1.2	23
110	Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. Journal of Diabetes and Its Complications, 2015, 29, 1024-1031.	1.2	22
111	Association of cardiovascular disease risk factors with coronary artery calcium volume versus density. Heart, 2018, 104, 135-143.	1.2	22
112	SGLT2 Inhibitors in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 631-633.	2.2	22
113	Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes. Diabetes Care, 2021, 44, 2098-2106.	4.3	22
114	Parathyroid Hormone and the Use of Diuretics and Calcium-Channel Blockers: The Multi-Ethnic Study of Atherosclerosis. Journal of Bone and Mineral Research, 2016, 31, 1137-1145.	3.1	21
115	Fibroblast Growth Factor 23 and Long-Term Cardiac Function. Circulation: Cardiovascular Imaging, 2020, 13, e011925.	1.3	21
116	Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 59-69.	2.2	21
117	Chronic kidney disease attenuates the plasma metabolome response to insulin. JCI Insight, 2018, 3, .	2.3	21
118	Noncontrast Cardiac Computed Tomography Image-Based Vertebral Bone Mineral Density. Academic Radiology, 2013, 20, 621-627.	1.3	20
119	Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrology, 2016, 17, 187.	0.8	20
120	A New Chapter for Diabetic Kidney Disease. New England Journal of Medicine, 2017, 377, 885-887.	13.9	20
121	Albuminuria, the High-Density Lipoprotein Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1483-1491.	1.1	20
122	Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 660-668.	2.2	20
123	Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. Diabetes Care, 2021, 44, 1499-1505.	4.3	20
124	Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health Study. Journal of the American Geriatrics Society, 2018, 66, 289-296.	1.3	19
125	Vitamin D Metabolic Ratio and Risks of Death and CKD Progression. Kidney International Reports, 2019, 4, 1598-1607.	0.4	19
126	Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. Lancet Diabetes and Endocrinology,the, 2022, 10, 509-518.	5.5	19

#	Article	IF	CITATIONS
127	Fibroblast Growth Factor 23 and Sudden Versus Non-sudden Cardiac Death: The Cardiovascular Health Study. American Journal of Kidney Diseases, 2015, 66, 40-46.	2.1	18
128	Associations of insulin resistance, inflammation and liver synthetic function with very low-density lipoprotein: The Cardiovascular Health Study. Metabolism: Clinical and Experimental, 2016, 65, 92-99.	1.5	18
129	Differences in 25-Hydroxyvitamin D Clearance by eGFR and Race: A Pharmacokinetic Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 188-198.	3.0	18
130	Echocardiographic Measures and Estimated GFR Decline Among African Americans: The Jackson Heart Study. American Journal of Kidney Diseases, 2017, 70, 199-206.	2.1	17
131	Validity of predictive equations for 24-h urinary potassium excretion based on timing of spot urine collection among adults: the MESA and CARDIA Urinary Sodium Study and NHANES Urinary Sodium Calibration Study. American Journal of Clinical Nutrition, 2018, 108, 532-547.	2.2	16
132	Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial. Diabetologia, 2021, 64, 437-447.	2.9	16
133	HDL in CKD: How Good Is the "Good Cholesterol?― Journal of the American Society of Nephrology: JASN, 2014, 25, 871-874.	3.0	15
134	Potassium and Glucose Measures in Older Adults: The Cardiovascular Health Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 255-261.	1.7	15
135	Fibroblast Growth Factor-23, Heart Failure Risk, and Renin–Angiotensin–Aldosterone-System Blockade in Hypertension: The MESA Study. American Journal of Hypertension, 2019, 32, 18-25.	1.0	15
136	Prediction of Kidney Drug Clearance: A Comparison of Tubular Secretory Clearance and Glomerular Filtration Rate. Journal of the American Society of Nephrology: JASN, 2021, 32, 459-468.	3.0	15
137	Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108204.	1.2	15
138	Plasma vitamin D is associated with fasting insulin and homeostatic model assessment of insulin resistance in young adult males, but not females, of the Jerusalem Perinatal Study. Public Health Nutrition, 2015, 18, 1324-1331.	1.1	14
139	Potassium Measures and Their Associations with Glucose and Diabetes Risk: The Multi-Ethnic Study of Atherosclerosis (MESA). PLoS ONE, 2016, 11, e0157252.	1.1	14
140	Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2016, 248, 224-229.	0.4	14
141	Urinary Proteomics Identifies Cathepsin D as a Biomarker of Rapid eGFR Decline in Type 1 Diabetes. Diabetes Care, 2022, 45, 1416-1427.	4.3	14
142	Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease. Physiological Reports, 2014, 2, e12010.	0.7	13
143	Serial Fibroblast Growth Factor 23 Measurements and Risk of Requirement for Kidney Replacement Therapy: The CRIC (Chronic Renal Insufficiency Cohort) Study. American Journal of Kidney Diseases, 2020, 75, 908-918.	2.1	13
144	Incidence and Risk Factors for Postcontrast Acute Kidney Injury in Survivors of Sudden Cardiac Arrest. Annals of Emergency Medicine, 2016, 67, 469-476.e1.	0.3	12

Ian H De Boer

#	Article	IF	CITATIONS
145	The kidney's role in systemic metabolism—still much to learn. Nephrology Dialysis Transplantation, 2017, 32, 588-590.	0.4	12
146	The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 296-301.	1.2	12
147	Bone mineral density and long-term progression of aortic valve and mitral annular calcification: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2021, 335, 126-134.	0.4	12
148	Standardised Outcomes in Nephrology – Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy. Trials, 2021, 22, 612.	0.7	12
149	Vitamin D in chronic kidney disease: is the jury in?. Kidney International, 2008, 74, 985-987.	2.6	11
150	Markers of kidney disease and risk of subclinical and clinical heart failure in African Americans: the Jackson Heart Study. Nephrology Dialysis Transplantation, 2016, 31, 2057-2064.	0.4	10
151	Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care, 2018, 41, 662-663.	4.3	10
152	A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes. American Journal of Nephrology, 2020, 51, 839-848.	1.4	10
153	Associations of Innate and Adaptive Immune Cell Subsets With Incident Type 2 Diabetes Risk: The MESA Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e848-e857.	1.8	10
154	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000461.	1.2	9
155	Meta-analysis across Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium provides evidence for an association of serum vitamin D with pulmonary function. British Journal of Nutrition, 2018, 120, 1159-1170.	1.2	9
156	Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2405-e2416.	1.8	9
157	Serum Phosphate and Retinal Microvascular Changes: The Multi-Ethnic Study of Atherosclerosis and the Beaver Dam Eye Study. Ophthalmic Epidemiology, 2017, 24, 371-380.	0.8	8
158	Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes. Diabetes Care, 2018, 41, 1132-1133.	4.3	8
159	Differences in proximal tubular solute clearance across common etiologies of chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 1916-1923.	0.4	8
160	Impact of Race on the Association of Mineral Metabolism With Heart Failure: the Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1144-e1151.	1.8	8
161	Relation of Serum Vitamin D to Risk of Mitral Annular and Aortic Valve Calcium (from the) Tj ETQq1 1 0.784314	rgBT /Ove 0.7	erloçk 10 Tf 5
162	Comparative Effects of Cholecalciferol and Calcitriol on Circulating Markers of CKD Mineral Bone Disorder. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 927-928.	2.2	7

#	Article	IF	CITATIONS
163	Pulmonary surfactant protein B carried by HDL predicts incident CVD in patients with type 1 diabetes. Journal of Lipid Research, 2022, 63, 100196.	2.0	7
164	Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics. Contemporary Clinical Trials, 2018, 74, 11-17.	0.8	6
165	Serum 25-hydroxyvitamin-D and nonalcoholic fatty liver disease: Does race/ethnicity matter? Findings from the MESA cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 114-122.	1.1	6
166	Validation of the 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 ratio as a biomarker of 25-hydroxyvitamin D3 clearance. Journal of Steroid Biochemistry and Molecular Biology, 2022, 217, 106047.	1.2	6
167	Vitamin D Deficiency. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1844-1846.	2.2	5
168	Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E175-E182.	1.8	5
169	Nephrology at a Crossroads. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 324-324.	2.2	5
170	Serum 25-Hydroxyvitamin D Concentrations Are Associated with Computed Tomography Markers of Subclinical Interstitial Lung Disease among Community-Dwelling Adults in the Multi-Ethnic Study of Atherosclerosis (MESA). Journal of Nutrition, 2018, 148, 1126-1134.	1.3	5
171	Blood pressure, antihypertensive medication use, and risk of erectile dysfunction in men with type I diabetes. Journal of Hypertension, 2019, 37, 1070-1076.	0.3	5
172	Retinal Capillary Nonperfusion on OCT-Angiography and Its Relationship to Kidney Function in Patients with Diabetes. Journal of Ophthalmology, 2020, 2020, 1-9.	0.6	5
173	Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. Nephrology Dialysis Transplantation, 2020, 35, 616-623.	0.4	5
174	Patient perspectives and involvement in precision medicine research. Kidney International, 2021, 99, 511-514.	2.6	5
175	Relationship Between Chronic Kidney Disease, Glucose Homeostasis, and Plasma Osteocalcin Carboxylation and Fragmentation. , 2021, 31, 248-256.		5
176	Clinical and biomarker modifiers of vitamin D treatment response: the Multi-Ethnic Study of Atherosclerosis. American Journal of Clinical Nutrition, 2022, 115, 914-924.	2.2	5
177	Comparative Safety of Phosphate Binders Without Proven Efficacy—How Did We Get Here?. JAMA Internal Medicine, 2019, 179, 749.	2.6	4
178	Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 525-537.	1.8	4
179	Associations of Dietary Intake with Urinary Melamine and Derivative Concentrations among Children in the GAPPS Cohort. International Journal of Environmental Research and Public Health, 2022, 19, 4964.	1.2	4
180	The expanding résumé of SGLT2 inhibitors. Lancet Diabetes and Endocrinology,the, 2019, 7, 585-587.	5.5	3

#	Article	IF	CITATIONS
181	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. American Journal of Kidney Diseases, 2022, 80, 132-138.	2.1	3
182	Genetic Variants Associated With Mineral Metabolism Traits in Chronic Kidney Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3866-e3876.	1.8	3
183	CJASN: What's Behind and What's Ahead. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 3-3.	2.2	2
184	Temporal Relationship of Glycemia With Cardiac Arrhythmias in Patients With Type 2 Diabetes and CKD. American Journal of Kidney Diseases, 2021, 77, 988-990.	2.1	2
185	Young Kidney Professionals' Perspectives and Attitudes about Consuming Scientific Information. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1587-1597.	2.2	1
186	The Multi-Ethnic Study of Atherosclerosis individual response to vitamin D trial: Building a randomized clinical trial into an observational cohort study. Contemporary Clinical Trials, 2021, 103, 106318.	0.8	1
187	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593.	4.3	1
188	The authors reply:. Kidney International, 2022, 101, 420-421.	2.6	1
189	Effect of Vitamin D3 (Cholecalciferol) Supplementation on Serum Vitamin D3 and 25-hydroxyvitamin D (25(OH)D) Concentrations Among Participants in the VITAL-DKD Study. Current Developments in Nutrition, 2020, 4, nzaa067_006.	0.1	0
190	Kidney Function in Patients With Type 2 Diabetes After Vitamin D Supplementation—Reply. JAMA - Journal of the American Medical Association, 2020, 323, 1411.	3.8	0
191	Environmental Exposure to Melamine-Related Compounds and Kidney Outcomes in Children. ISEE	0.0	0